作者
Jay P Patel, Mithat Gönen, Maria E Figueroa, Hugo Fernandez, Zhuoxin Sun, Janis Racevskis, Pieter Van Vlierberghe, Igor Dolgalev, Sabrena Thomas, Olga Aminova, Kety Huberman, Janice Cheng, Agnes Viale, Nicholas D Socci, Adriana Heguy, Athena Cherry, Gail Vance, Rodney R Higgins, Rhett P Ketterling, Robert E Gallagher, Mark Litzow, Marcel RM Van Den Brink, Hillard M Lazarus, Jacob M Rowe, Selina Luger, Adolfo Ferrando, Elisabeth Paietta, Martin S Tallman, Ari Melnick, Omar Abdel-Wahab, Ross L Levine
发表日期
2012/3/22
期刊
New England Journal of Medicine
卷号
366
期号
12
页码范围
1079-1089
出版商
Massachusetts Medical Society
简介
Background
Acute myeloid leukemia (AML) is a heterogeneous disease with respect to presentation and clinical outcome. The prognostic value of recently identified somatic mutations has not been systematically evaluated in a phase 3 trial of treatment for AML.
Methods
We performed a mutational analysis of 18 genes in 398 patients younger than 60 years of age who had AML and who were randomly assigned to receive induction therapy with high-dose or standard-dose daunorubicin. We validated our prognostic findings in an independent set of 104 patients.
Results
We identified at least one somatic alteration in 97.3% of the patients. We found that internal tandem duplication in FLT3 (FLT3-ITD), partial tandem duplication in MLL (MLL-PTD), and mutations in ASXL1 and PHF6 were associated with reduced overall survival (P=0.001 for FLT3-ITD, P=0.009 for MLL-PTD, P=0.05 for ASXL1, and P=0.006 for …
引用总数
学术搜索中的文章
JP Patel, M Gönen, ME Figueroa, H Fernandez, Z Sun… - New England Journal of Medicine, 2012